"Through Covifor, we hope to reduce the treatment time of a patient in a hospital, thereby reducing the increasing pressure on the medical infrastructure, overburdened currently due to accelerating Covid-19 infection rates. We are working closely with the government and medical community to make Covifor quickly accessible to both public and private healthcare settings across the country," said M. Srinivasa Reddy, Managing Director, Hetero Healthcare.

What is Covifor?

Covifor is the first generic brand of Remdesivir which is indicated for the treatment of Covid-19 patients in adults and children, hospitalised with severe symptoms of the disease. The drug is available in 100 mg vial (injectable). It needs to be administered intravenously in a hospital, or critical care setting, under the supervision of a registered medical practitioner.

Covifor is anticipated to play a significant role in bringing down the mortality rates caused by Covid-19, given its proven positive clinical outcomes, the company added.

• The drug will be available in 100 mg injectable form which has to be administered intravenously in a hospital setting under the supervision of a healthcare professional. It is not a drug you can take at home. 
• The company is sure about enough stock to cater to the present needs of the medicine. 
• The COVID-19 treatment by Covifor will cost not more than 30,000 per patient. Six dozes of the medicine will be given in this timeframe.